![](/wp-content/uploads/2021/10/Oct-15-2021-Feature-Image.png)
$599
Forxiga Pediatric Indication and Generic Sitagliptin Receive Positive CHMP Opinions
Two cardiometabolic-related news items have been observed: AstraZeneca’s Forxiga received a positive CHMP opinion to include treatment of children aged 10 years and older with T2DM; and generic sitagliptin received a positive CHMP opinion. Below, FENIX provides highlights and insights for the respective news items.